Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online:: 470
ORIGINAL ARTICLE
Year : 2010  |  Volume : 13  |  Issue : 3  |  Page : 110-119

Use of chloroquine in uncomplicated falciparum malaria chemotherapy : The past, the present and the future


1 Department of Clinical Pharmacology & Therapeutics, College of Medical Sciences, University of Maiduguri, Nigeria
2 Department of Veterinary Physiology, Pharmacology & Biochemistry, Faculty of Veterinary Medicine, University of Maiduguri, Nigeria
3 Department of Pharmacology & Therapeutics, College of Medicine, University of Ibadan, Nigeria

Correspondence Address:
Balogun S T
Department of Clinical Pharmacology & Therapeutics, College of Medical Sciences, University of Maiduguri
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Chloroquine is a 4-aminoquinoline discovered over five decades ago for treatment of uncomplicated malaria. It was widely used as first line treatment and prophylaxis for individuals going into malaria endemic regions. It was initially highly effective against the four Plasmodium species (P. falciparum, P. malaria, P. ovale and P. vivax) infecting human. It is also effective against gametocytes except those of P. falciparum. Resistance of P. falciparum to chloroquine is widespread and led to discontinuation of chloroquine in malaria treatment by most countries. In recent times, evidences are emerging for chloroquine to probably secure its original place in treatment of acute uncomplicated falciparum malaria. This would be a welcome idea since chloroquine is readily available, relatively safer and cheaper than most currently use antimalarial drugs. Thus, researchers should intensify efforts on periodic in vitro monitoring of chloroquine efficacy; clinicians should further discourage use of chloroquine until efficacy is remarkably restored and pharmaceutical industries should look into potential chloroquine and chloroquine-resistance reversal fixed and non-fixed doses combinations.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed937    
    Printed40    
    Emailed0    
    PDF Downloaded106    
    Comments [Add]    

Recommend this journal